- Resverlogix’s (RVX) apabetalone has demonstrated a medical first in patients with chronic kidney disease
- Apabetalone was associated with a 52 per cent reduction in MACE events such as CVD death and heart failure compared to the placebo
- Patients in the study had stage 3 or worse CKD, diabetes and a recent acute coronary syndrome
- The finding demonstrates that apabetalone may offer a safe and effective treatment option for this high-risk group of patients
- Resverlogix is a clinical-stage biotechnology company
- Resverlogix (RVX) is up by 1.08 per cent and is currently trading at C$0.94 per share
Resverlogix’s (RVX) apabetalone has demonstrated a medical first in patients with chronic kidney disease.
The company is announcing the recent publication of an article in the peer-reviewed Clinical Journal of the American Society of Nephrology entitled,
Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial.
- Apabetalone treatment was associated with a 52 per cent hazard reduction for MACE events such as CVD death and heart failure compared to the placebo
- A statistically significant reduction in alkaline phosphatase, a reported risk marker for CKD, was observed in patients with CKD after 24 weeks of apabetalone treatment
- Fewer serious adverse events were also observed in the apabetalone treated group compared to the placebo
The prespecified analysis illustrates that treatment with apabetalone was associated with a lower incidence of MACE in patients with stage 3 or worse CKD, diabetes and a recent acute coronary syndrome.
Dr. Kam Kalantar-Zadeh of the University of California Irvine, member of the BETonMACE Clinical Steering Committee, and lead author of the paper, commented,
“To my knowledge, this is the first time that a cardiovascular risk-reducing intervention – apabetalone – has shown such an improvement in clinical outcomes in patients with chronic kidney disease. This is also the first time that an epigenetic modulator in the form of an oral pill has been studied in CKD.
These data warrant further clinical research and development of apabetalone in patients with high-risk CKD.”
Donald McCaffrey, President and CEO of Resverlogix, commented,
“The pronounced reduction in MACE seen in BETonMACE CKD patients highlights the potential benefit these patients could receive from apabetalone treatment. Patients with CKD, type-2 diabetes and established cardiovascular disease will be the primary target patient population for our upcoming registration-enabling study, BETonMACE2.”
Resverlogix is a clinical-stage biotechnology company.
Resverlogix (RVX) is up by 1.08 per cent and is currently trading at C$0.94 per share as of 2:48 pm ET.